Nitrosated and nitrosylated prostaglandins, compositions and methods of use
View Patent ↗The invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E 1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions.
1. A compound selected from the group consisting of:
(2S,3S)-2,3,4-tris(nitroxy)butyl 7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]heptanoate;
(2S)-2,3-bis(nitroxy)propyl 7-[5-((1E)(3S)-3-(nitrooxyoct-1-enyl)(1R,4R,5R)-4-(nitrooxy)-2-oxocyclopentyl]heptanoate;
3-nitrooxy-2,2-bis(nitrooxymethyl)propyl 7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]heptanoate;
3-nitrooxy-2,2-bis[(nitrooxy)methyl]propyl 7-[5-[(1E)(3S)-3-(nitrooxyoct-1-enyl)(1R,4R,5R)-4-nitrooxy-2-oxocyclopentyl]heptanoate;
methyl 7-[5-((1E)(3S)-3-nitroxyoct-1-enyl)(1R,4R,5R)-4-nitrooxy-2-oxocyclopentyl]heptanoate;
2-[2-(nitrosothio)adamantan-2-yl]ethyl 7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]heptanoate;
[{1-[(4-methylphenyl)sulfonyl]-4-(nitrosothiol)-4-piperidyl}methyl 7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]heptanoate; and
2-methyl-2-(nitrosothio)propyl 7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]heptanoate; or a pharmaceutically acceptable salt thereof.
2. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
3. The composition of claim 2 , further comprising (i) at least one vasoactive agent; (ii) at least one nitric oxide donor compound; or (iii) at least one vasoactive agent and at least one nitric oxide donor compound.
4. The composition of claim 3 , wherein the vasoactive agent is a potassium channel activator, a calcium channel blocker, an α-blocker, a β-blocker, a phosphodiesterase inhibitor, adenosine, an ergot alkaloid, a vasoactive intestinal peptide, a dopamine agonist, an opioid antagonist, an endothelin antagonist or a mixture thereof.
5. The composition of claim 4 wherein the vasoactive agent is an α-blocker or a phosphodiesterase inhibitor.
6. The composition of claim 5 , wherein the α-blocker is phentolamine, prazosin, doxazosin, terazosin, yohimbine or moxisylyte and the phosphodiesterase inhibitor is papaverine, zaprinast, sildenafil or IC 351, or a mixture thereof.
7. A kit comprising at least one compound selected from the group consisting of:
(2S,3S)-2,3,4-tris(nitroxy)butyl 7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]heptanoate;
(2S)-2,3-bis(nitroxy)propyl 7-[5-((1E)(3S)-3-(nitrooxyoct-1-enyl)(1R,4R,5R)-4-(nitrooxy)-2-oxocyclopentyl]heptanoate;
3-nitrooxy-2,2-bis(nitrooxymethyl)propyl 7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]heptanoate;
3-nitrooxy-2,2-bis[(nitrooxy)methyl]propyl 7-[5-[(1E)(3S)-3-(nitrooxyoct-1-enyl)(1R,4R,5R)-4-nitrooxy-2-oxocyclopentyl]heptanoate;
methyl 7-[5-((1E)(3S)-3-nitroxyoct-1-enyl)(1R,4R,5R)-4-nitrooxy-2-oxocyclopentyl]heptanoate;
2-[2-(nitrosothio)adamantan-2-yl]ethyl 7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]heptanoate;
[{1-[(4-methylphenyl)sulfonyl]-4-(nitrosothiol)-4-piperidyl}methyl 7-[5-((1E)(3S)-3 -hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]heptanoate; and
2-methyl-2-(nitrosothio)propyl 7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]heptanoate; or a pharmaceutically acceptable salt thereof.
8. The kit of claim 7 , further comprising further comprising (i) at least one vasoactive agent; (ii) at least one nitric oxide donor compound; or (iii) at least one vasoactive agent and at least one nitric oxide enhancing compound.
9. The kit of claim 8 , wherein the (i) at least one vasoactive agent; (ii) at least one nitric oxide donor compound; or (iii) at least one vasoactive agent and at least one nitric oxide donor compound are in the form of separate components in the kit.